Investment Rating - The investment rating for the company is "Buy" with a target price of HKD 58.5, while the current stock price is HKD 49.85 as of November 18, 2024 [2]. Core Insights - The company achieved significant growth during the Double 11 shopping festival, with its brands 可复美 and 可丽金 recording GMV growth of over 80% and 150% respectively [5][7]. - The company has established itself as an industry leader by publishing the first group standard for fermented ginseng powder, enhancing its market position [10]. Financial Performance - The total market capitalization of the company is HKD 51.257 billion, with a total share capital of 1.028 billion shares [3]. - Revenue projections for 2024, 2025, and 2026 are HKD 5.064 billion, HKD 6.839 billion, and HKD 8.592 billion respectively, with corresponding growth rates of 43.7%, 35.0%, and 25.6% [11]. - The net profit attributable to the parent company for the same years is projected to be HKD 1.922 billion, HKD 2.440 billion, and HKD 2.872 billion, with growth rates of 32.4%, 26.9%, and 17.7% respectively [11]. Shareholder Structure - The shareholder structure indicates that the founding couple holds 57% of the shares, while other shareholders hold the remaining 43% [4]. Market Performance - The company's stock has shown a relative return of 34.89% over the past twelve months [13].
巨子生物：双11再创佳绩，首个发酵人参粉领域团队标准发布